Journal Scans
Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
Biomarker-Based Outcomes With Second-Line Therapy in Advanced NSCLC
JY Douillard, FA Shepherd, V Hirsh, T Mok, MA Socinski, R Gervais, ML LiaoL, H Bischoff, M Reck, MV Sellers, CL Watkins, G Speake, AA Armour, ES Kim
20091128
2009 Dec 28
J Clin Oncol
Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
J Clin Oncol. 2009 Dec 28; Epub ahead of print, JY Douillard, FA Shepherd, V Hirsh, T Mok, MA Socinski, R Gervais, ML LiaoL, H Bischoff, M Reck, MV Sellers, CL Watkins, G Speake, AA Armour, ES Kim
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) gefitinib has proven efficacy and is well tolerated when used as second-line therapy in patients with advanced non–small-cell lung cancer (NSCLC). Tumors that overexpress or exhibit high copy number mutations of EGFR respond favorably to EGFR-TKI treatment. The Iressa NSCLC Trial Evaluating Response and Survival vs Taxotere (INTEREST) study was a randomized, phase III trial that showed noninferiority of gefitinib to docetaxel...
